

Christine M Fennessey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6576285/publications.pdf>

Version: 2024-02-01

17
papers

567
citations

840776

11
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

828
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent anti-viral activity of a trispesific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	6.4	19
2	Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy. Journal of Clinical Investigation, 2021, 131, .	8.2	11
3	Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques. PLoS Pathogens, 2021, 17, e1009565.	4.7	10
4	Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir. PLoS Pathogens, 2021, 17, e1009686.	4.7	7
5	Blocking $\alpha 4 \beta 7$ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. Science Translational Medicine, 2021, 13, .	12.4	11
6	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 494-502.	7.1	9
7	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood, 2020, 136, 1722-1734.	1.4	37
8	Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo. Nature, 2020, 578, 160-165.	27.8	210
9	Defining early SIV replication and dissemination dynamics following vaginal transmission. Science Advances, 2019, 5, eaav7116.	10.3	30
10	Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV in vivo. Retrovirology, 2019, 16, 11.	2.0	3
11	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	4.7	20
12	<i>In Vivo</i> Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses. Journal of Virology, 2019, 94, .	3.4	24
13	Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection. Journal of Virology, 2019, 94, .	3.4	23
14	Predictors of SIV recrudescence following antiretroviral treatment interruption. ELife, 2019, 8, .	6.0	18
15	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. Journal of Virology, 2018, 92, .	3.4	12
16	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathogens, 2017, 13, e1006359.	4.7	77
17	Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events. Journal of Virology, 2014, 88, 8077-8090.	3.4	46